Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono Increases Oncology Medical Representatives To Expand Japanese Market

This article was originally published in PharmAsia News

Executive Summary

With the recent market launch of colon cancer drug Erbitux (cetuximab), German drug maker Merck Serono plans to add 20 to 40 oncology medical representatives in three years in Japan. Merck Serono currently has 60 oncology MRs in Japan. Merck Serono's president estimated that as colon cancer will likely top cancer cases in Japan by 2020, Erbitux could become a blockbuster drug. (Click here for more - Japanese language

You may also be interested in...

YM Bioscience's EGFR-targeting Drug Goes Into Phase III Trials In Singapore

SHANGHAI - National Cancer Centre of Singapore will sponsor YM Bioscience's nimotuzumab for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck, the company recently announced

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

BioNTech Looks To AI Partnership To Accelerate Drug Discovery

The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts